¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ATROPINE JE2 AMP."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® atropine ÇÑ±Û ¾ÆÆ®·ÎÇÉ
¼³¸í   
  ½Å°æÀü´Þ¹°ÁúÀÇ ÇÑ °¡Áö·Î ±ÙÀ°À» Áö¹èÇϴ ½Å°æÀÇ ¸»´Ü¿¡¼­ ºÐºñµÇ¾î ±ÙÀ°ÀÇ ¼öÃàÀ» À¯µµÇϱ⵵ Çϸç, ºÎ±³°¨½Å°æÀÇ ¸»´Ü¿¡¼­ ºÐºñµÇ¾î ºÎ±³°¨½Å°æÀÇ Àü´ÞÀ» ´ã´çÇϱ⵵ Çϰí, ³úÀÇ ½Å°æ¼¼Æ÷¿¡¼­µµ ºÐºñµÇ¾î ¿©·¯°¡Áö ÀÛ¿ëÀ» Çϴ ¾Æ¼¼Æ¿Äݸ°À̶ó´Â ¹°ÁúÀÇ ¿ªÇÒÀ» Â÷´ÜÇϴ ¹°ÁúÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atropine
    ¾ÆÆ®·ÎÇÉ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atropine
    ¾ÆÆ®·ÎÇÉ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atropine
    ¾ÆÆ®·ÎÇÉ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Cycle AMP
    °í¸®¸ð¾çAMP, ȯ½Ä¾Æµ¥³ë½Å¸ð³ëÆ÷½ºÆäÀÌÆ®, »çÀÌŬ¸¯AMP
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adenosine monophosphate =AMP
    ÀÏÀÎ»ê¾Æµ¥³ë½Å.
  • cAMP=>cyclic AMP
    ȯ½ÄAMP
  • cyclic AMP
    °í¸® AMP
  • cyclic AMP ; cyclic adenosine mono pho sph ate
    °í¸®¸ð¾ç AMP.¾à¸®È¯ ½Ä±¸¾Æ³ë½Å¸ð³ëÆ÷½ºÆäÀÌÆ®, »çÀÌŬ¸¯AMP, cAMP cyclic aclenosine 3 , 5 monophate
  • cyclic AMP-dependent kinase
    °í¸® AMP ÀÇÁ¸¼º Ű³ªÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atropine
    ¾ÆÆ®·ÎÇÉ
  • AA-AMP
    (å²) aminoacyl adenylate
  • AMP
    "(å²) adenosine monophosphate, adenylic acid adenosine 5'-monophosphate"
  • AMP
    (å²) adenosine monophosphate
  • AMP-kinase
    AMPÄ«À̳×À̽º
  • cyclic AMP receptor protein
    °í¸®AMP ¼ö¿ëü ´Ü¹éÁú(áôé»ô÷Ó±ÛÜòõ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ACT achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ...
AS acetylstrophanthidin; acidified serum; acoustic schwannoma; acoustic stimulation; active sarcoidosis...
AT abdominal thrusts; achievement test; Achilles tendon; Achard-Thiers [syndrome]; adaptive thermogenes...
LANE lidocaine, atropine, naloxone, epinephrine [drugs that may be administered via endotracheal tube]
NAVEL naloxone, atropine, Valium, epinephrine, lidocaine
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
DBcyclic AMP Dibutyryl cyclic AMP
A Atropine
AT Atropine
ATR Atropine
DASE Dobutamine atropine stress echocardiography
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • atropine therapy
    ¾ÆÆ®·ÎÇÉ Ä¡·á, ¾ÆÆ®·ÎÇÉ ¿ä¹ý
  • c-AMP level
    ȯ½Ä AMP ·¹º§
  • cyclic AMP
    ȯ»ó AMP, °í¸®¸ð¾ç AMP, ȯ½Ä ¾Æµ¥³ë½Å ¸ð³ëÆ÷½ºÆäÀÌÆ®, »çÀ̱۸¯ AMP, cAMP
    cyclic adelenosine 3',5'-mono
  • cyclic AMP system
    ȯ»ó AMP °è
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
atropine <drug> A toxic alkaloid extracted from belladonna and other members of thenightshade family, it is typically used to dilate the eye and to stopmuscular spasms.
Pharmacologic action: Parasympatholytic. Competitive blockade of acetylcholine at muscarinic receptors. Increases sinus node automaticity and AV conduction.
Uses: Treat bradycardia, asystole, and AV block
Dose: 0.5 - 1.0 mg for bradycardia every 3 - 5 min to a total dose of 0.04 mg/kg. Doses smaller than 0.5 mg can cause a paradoxical bradycardia due to sympathomimetic effects Typically 3 mg is adequate to completely block vagal effects Atropine is well absorbed via endotracheal route - administer 1-2 mg diluted in 10 mL sterile water or normal saline.
Potential complications: 1. Tachyarrhythmias 2. Exacerbation of myocardial ischemia 3. Low dose may cause paradoxical bradycardia 4. Dry mouth, urinary retention, flushed and hot skin 5. Crosses blood-brain barrier which can cause delirium
Note: The denervated heart will not respond to atropine.
(15 Mar 2000)
atropine dehydrase <enzyme> Proposed mechanism for conversion of atropine or scopolamine to apoatropine or aposcopolamine via a mechanism using hydroxysteroid sulfotransferase by guinea pig liver
Registry number: EC 2.8.2.-
Synonym: scopolamine dehydrase
(26 Jun 1999)
atropine derivatives Analogs and derivatives of atropine.
(12 Dec 1998)
atropine methonitrate The methylnitrate of atropine, with the same actions and uses as atropine, but less lipid-soluble and hence with fewer central nervous system effects; a quaternary compound.
(05 Mar 2000)
atropine methylbromide A quaternary derivative of atropine that is less lipid soluble and hence produces fewer central nervous system actions; a cycloplegic.
Synonym: atropine methylbromide.
(05 Mar 2000)
atropine sulfate An anticholinergic; a widely used soluble salt of atropine.
(05 Mar 2000)
atropine test If an injection of atropine relieves bradycardia, the condition is due to action of the vagus; if it does not, the condition may be due to an affection of the heart itself.
Synonym: atropine test.
(05 Mar 2000)
AMP <abbreviation> Adenosine monophosphate; specifically, the 5'-monophosphate unless modified by a numerical prefix.
See: adenylic acid.
(05 Mar 2000)
AMP-activated protein kinase kinase <enzyme> An endogenous kinase kinase; reactivates the inactive form of AMP-activated protein kinase (AMP-pk); phosphorylates the 63-kD subunit of AMP-pk
Registry number: EC 2.7.1.-
Synonym: AMP-pk reactivator, hmg CoA reductase kinase kinase
(26 Jun 1999)
AMP deaminase <enzyme> An enzyme that catalyses the deamination of AMP to imp.
Chemical name: AMP aminohydrolase
Registry number: EC 3.5.4.6
(12 Dec 1998)
receptors, cyclic AMP Cell surface proteins that bind cyclic AMP with high affinity and trigger intracellular changes which influence the behaviour of cells. The best characterised cyclic AMP receptors are those of the slime mold dictyostelium discoideum. The transcription regulator cyclic AMP receptor protein of prokaryotes is not included nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins which are the regulatory subunits of cyclic AMP-dependent protein kinases.
(12 Dec 1998)
polyphosphate AMP phosphotransferase <enzyme> From acinetobacter; catalyses (polyphosphate)n and AMP to (polyphosphate)n-1 and ADP
Registry number: EC 2.7.4.-
Synonym: pamp phosphotransferase
(26 Jun 1999)
cyclic AMP <molecular biology> 3'5' cyclic ester of AMP. The first second messenger hormone signalling system to be characterised. Generated from ATP by the action of adenyl cyclase that is coupled to hormone receptors by G-proteins (GTP-binding proteins). CAMP activates a specific (cAMP dependent) protein kinase and is inactivated by phosphodiesterase action giving 5'AMP. Also functions as an extracellular morphogen for some slime moulds.
(18 Nov 1997)
cyclic AMP-dependent protein kinase Enzymes which attach phosphate groups to the serine or tyrosine amino acids on proteins as a means of regulating the proteins' activity in metabolic reactions.
(09 Oct 1997)
cyclic AMP-dependent protein kinases <enzyme> A group of enzymes that are dependent on cyclic AMP and catalyze the phosphorylation of serine or threonine residues on proteins.
Registry number: EC 2.7.10.-
(12 Dec 1998)
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 1 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
Á¦ÀÏȲ»ê¾ÆÆ®·ÎÇÉÁÖ»ç¾× - »õâ
Á¦ÀÏÁ¦¾à
A04900241 Atropine Sulfate
Àü¹®ÀǾàǰ | ±Þ¿© | ºÐ¾÷¿¹¿ÜÀǾàǰ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • atropine
    ¾ÆÆ®·ÎÇÉ
  • atropine
    ¾ÆÆ®·¯ÇÉ(Áø°æÁ¦·Î ¾²ÀÌ´Â µ¶¾à)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á